Allergy Therapeutics plc
AGY.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £21,014 | £34,030 | £21,627 | £33,572 |
| % Growth | -38.2% | 57.3% | -35.6% | – |
| Cost of Goods Sold | £16,746 | £13,168 | £12,410 | £13,052 |
| Gross Profit | £4,268 | £20,862 | £9,217 | £20,520 |
| % Margin | 20.3% | 61.3% | 42.6% | 61.1% |
| R&D Expenses | £7,730 | £7,647 | £11,514 | £11,386 |
| G&A Expenses | £13,904 | £5,183 | £11,652 | £11,138 |
| SG&A Expenses | £21,060 | £20,034 | £21,021 | £21,360 |
| Sales & Mktg Exp. | £14,549 | £4,654 | £9,369 | £10,222 |
| Other Operating Expenses | -£1,836 | £0 | £0 | -£340 |
| Operating Expenses | £26,954 | £27,681 | £32,535 | £32,406 |
| Operating Income | -£22,587 | -£6,819 | -£23,318 | -£11,886 |
| % Margin | -107.5% | -20% | -107.8% | -35.4% |
| Other Income/Exp. Net | -£6,396 | -£4,543 | -£932 | -£3,030 |
| Pre-Tax Income | -£29,082 | -£11,362 | -£24,250 | -£14,916 |
| Tax Expense | -£35 | -£277 | £315 | £735 |
| Net Income | -£29,047 | -£11,085 | -£24,565 | -£15,651 |
| % Margin | -138.2% | -32.6% | -113.6% | -46.6% |
| EPS | -0.006 | -0.002 | -0.007 | -0.006 |
| % Growth | -165.2% | 64.6% | -12.1% | – |
| EPS Diluted | -0.006 | -0.002 | -0.007 | -0.006 |
| Weighted Avg Shares Out | 4,766,440 | 4,766,440 | 3,758,505 | 2,698,914 |
| Weighted Avg Shares Out Dil | 4,766,440 | 4,766,440 | 3,758,505 | 2,720,224 |
| Supplemental Information | – | – | – | – |
| Interest Income | £169 | £213 | £126 | £159 |
| Interest Expense | £3,880 | £2,963 | £1,005 | £3,189 |
| Depreciation & Amortization | £2,237 | £1,935 | £2,205 | £2,114 |
| EBITDA | -£22,965 | -£6,464 | -£21,040 | -£9,700 |
| % Margin | -109.3% | -19% | -97.3% | -28.9% |